What is JNJ's current stock price?

As of now, JNJ is trading at $166.07, with a daily change of -0.98%.

What are JNJ stock strengths?

JNJ strengths include Pays a reliable dividend, Earnings are forecast to grow, Trading below its fair value, .

What are the risks associated with JNJ stock?

JNJ Key risk is its Low Risk Level, .

What is JNJ next earnings date?

JNJ next earnings report is scheduled for Apr 15, 2025.

What is JNJ's current stock rating?

JNJ's current stock rating is Hold.

Should I buy JNJ stock right now?

Based on the current rating of Hold, it is advisable to consider Hold as your next step with JNJ stock.

Is JNJ a Strong Buy right now?

JNJ's current stock rating is Hold, which indicates whether it is a Strong Buy, Buy, Hold, Sell, or Strong Sell.

What does a 'Strong Buy' rating mean for JNJ?

A 'Strong Buy' rating for JNJ indicates that analysts are highly confident in the stock's potential for future growth.

What does a 'Strong Sell' rating mean for JNJ?

A 'Strong Sell' rating for JNJ suggests that analysts anticipate the stock will decline significantly and may not be a good investment.

What factors influence JNJ's stock rating?

JNJ's stock rating is influenced by factors such as market trends, earnings reports, risk factors, and overall sentiment from analysts.

Johnson & Johnson (JNJ) Stock Analysis and Insights

LOGIN

Market Overview Trending Stocks Stock Screener Trade Ideas

Top Rated Most Active Strong Potential Positive Momentum Earnings Calendar

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist

JNJ

Johnson & Johnson

$166.07

-$1.65 | -0.98%

Overview

Analysis

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Open

$ 167.20

MKT CAP

$ 399.67B

High

$ 167.30

VOL

$ 5.91M

Low

$ 165.05

AVG VOL

$ 9.50M

Chart

150.38

149.23

161.6

155.23

1year

6month

3month

1month

JNJ Latest Headlines +

Genmab upgraded at William Blair despite J&Js exit from program.

Today

Rating

Why Is Protagonist Therapeutics Stock Trading Higher On Monday?. On Monday ) announced topline results from ANTHEM-UC Phase 2b study of icotrokinra (JNJ-2113) in adults with moderately to severely active .The study conducted by Protagonist’.s collaboration partner Additionally the study demonstrated clinically meaningful differences versus placebo in key secondary endpoints of clinical remission symptomatic remission and endoscopic .All three doses of once daily icotrokinra met the primary

Mon Mar 10, 2025

Activity

Momentum

JNJ Halts Development of Depression Drug Over Efficacy Concerns. While J&J is yet to give up on aticaprant it decides to stop developing the drug for major depressive disorder due to a lack of sufficient efficacy.

Fri Mar 7, 2025

Activity

Pfizer boosts anti-obesity efforts: adds former J&J exec. as chief internal medicine officer.

Fri Mar 7, 2025

Activity

Pfizer Vs. Johnson & Johnson: Whos The Better Bargain For Investors.

Fri Mar 7, 2025

Potential

Neumora cut to Hold at Stifel after J&Js VENTURA exit.

Fri Mar 7, 2025

Rating

IVE PG JNJ JPM: Large Inflows Detected at ETF. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares S&.P 500 Value ETF (Symbol: IVE) where we have detected an approximate $2.2 billion dollar inflow -- thats a 6.2% increase week over week

Thu Mar 6, 2025

Potential

What 14 Analyst Ratings Have To Say About Johnson & Johnson. 14 analysts have shared their evaluations of Johnson &. Johnson (NYSE:) during the recent three months expressing a mix of ish and bearish perspectives.In the table below you'.ll find a summary of their recent ratings revealing the shifting sentiments over the past 30 days and comparing them to the previous months.1490000100011000360010100Providing deeper insights analysts have established 12-month price targets indicating an av

Wed Mar 5, 2025

Activity

Momentum

Johnson & Johnson (JNJ) Presents at 45th Annual TD Cowen Healthcare Conference (Transcript).

Tue Mar 4, 2025

Activity

Johnson & Johnson To Present At TD Cowen Healthcare Conference. Webast At 11:10 AM ET . (RTTNews) - Johnson & Johnson (JNJ) will present at the 45th Annual TD Cowen Healthcare Conference.

Tue Mar 4, 2025

Activity

Explore our JNJ Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored JNJ Stock Strategies
Effective Risk Management

FIND US ON

Receive our JNJ Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

Ideas

Earnings

Overview

Analysis

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

JNJ

Johnson & Johnson

$166.07

-$1.65 | -0.98%

Chart

150.38

149.23

161.6

155.23

1year

6month

3month

1month

Discover JNJ Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of JNJ. We're here to help you make informed investment decisions today.

FIND US ON

Receive our JNJ Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

JNJ Stock trends

JNJ Stock performance

JNJ Stock analysis

JNJ investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

JNJ Stock Analysis for the Last 90 Days

JNJ Risk Level

JNJ Analysts Opinion

JNJ Street Consensus

JNJ Performance Sentiment

Technical Price Levels

JNJ Financial Health

JNJ Fair Price vs Current Price

Explore our JNJ Stock insights

Receive our JNJ Daily Alerts

JNJ Stock Analysis for the Last 90 Days

JNJ Street Consensus

Technical Price Levels

JNJ Fair Price vs Current Price

Discover JNJ Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of JNJ. We're here to help you make informed investment decisions today.

Receive our JNJ Daily Alerts